A Christmas Eve Gift: Two Stocks to Watch Now, Three More for Those Ready to Win

First off, I want to say how much I appreciate all of you—our loyal Marathon Money members who have stuck with us and the new ones who joined us this year. Whether you’ve been here for years or just hopped on board, you’re the reason we do what we do. Your trust and commitment mean everything, and I can’t thank you enough for being part of this journey.

Now, let’s get to it. It’s Christmas Eve, and while most people are winding down, true investors know the market never sleeps. That’s why I’m sharing five stocks that I believe have the potential to make big moves in 2025. Two of these are on me—free for everyone as a little gift for the holiday season. The other three? They’re for those of you ready to take that next step, dig a little deeper, and invest in the kind of insights that make a difference.

Let’s dive into these picks and see what 2025 could hold for us.

Immunome Inc. (IMNM)

For my first stock pick, I’m putting Immunome Inc. (IMNM) on the radar. This is a biotech company that focuses on developing innovative immune therapies, and while it’s not without its risks, it’s got a few key factors that catch my attention.

Here’s why:

• Insider Confidence: Insiders own nearly 18% of the company, which is a strong indicator that those closest to the business believe in its potential.
• Institutional Backing: Institutions hold over 81% of the float, showing significant interest from major players in the market.
• Gross Margin Strength: Despite its challenges, Immunome boasts a gross margin of over 82.5%, which is impressive in this space.
• Potential for Growth: The stock has seen significant volatility but remains up 20.23% over the past year, with a target price of $30, offering potential upside from its current price of around $11.

That said, Immunome is not without its challenges. Its earnings per share (EPS) and profit margin reflect the risks associated with companies in early stages of biotech development. However, for those with a higher risk tolerance looking for big upside potential, this could be worth considering.

This is your first stock to dig into as we head into 2025. Ready to see the rest of the list? Three more picks await for those ready to dive deeper. Stay tuned for the second free pick next!

Let’s break it down with a clear +/- analysis for Immunome Inc. (IMNM), so you can weigh the opportunity:

Positives (+):

• Strong Insider Ownership: 17.98% of the company is owned by insiders, signaling confidence from those who know it best.
• Institutional Support: Institutions hold 81.84% of the float, highlighting interest from major investors.
• High Gross Margins: At 82.58%, the gross margin is a standout in the biotech sector, showing operational efficiency.
• Strong Potential Upside: The stock has a 52-week high of $30.96, and analysts’ target price is around $30, offering significant room to grow from its current price of $11.29.
• Low Debt: A debt-to-equity ratio of just 0.01 shows the company is not overleveraged, which is crucial for stability in the biotech space.

Negatives (-):

Market Cap vs. Revenue: At a market cap of $704.68M and only $10.13M in sales, the price-to-sales ratio of 69.56 is exceptionally high.

Unprofitable: With a negative EPS of -8.12 and a profit margin of -3,014%, the company is burning cash heavily.

Volatile Performance: The stock has a beta of 1.88 and high volatility (6.27%-7.59%), making it a risky play for conservative investors.

Declining Sales: Sales are down 18.37% quarter over quarter, and operational margins are at a staggering -3,068%.

Short Interest: 19.12% of the float is shorted, indicating skepticism among investors about the company’s near-term prospects.

Dynavax Technologies Corp. (DVAX)

Dynavax Technologies (DVAX) is a biotech company with a focus on innovative vaccine development, making it a compelling pick for 2025. Here’s why I think it deserves a spot on your watchlist:

Why DVAX?

The company has carved out a niche in vaccines, leveraging its adjuvant technology to develop products like HEPLISAV-B, a hepatitis B vaccine. As vaccine development continues to evolve, Dynavax is positioned to benefit from increased demand in both emerging markets and specialized areas like adult immunizations. Additionally, its ability to generate consistent revenues from partnerships with other pharmaceutical companies is an important growth lever.

Moreover, the biotech industry often sees significant moves based on clinical results, regulatory approvals, and partnerships. With Dynavax’s robust pipeline and focus on innovation, the potential for a breakout in the coming year is high.

Positives (+):

• Strong Institutional Ownership: Institutions hold a whopping 103.79% of the float, a strong vote of confidence from major market players.
• Improving Earnings: EPS growth of 496% this year highlights significant progress toward profitability.
• Financial Health: A current ratio of 13.23 and a quick ratio of 12.34 show the company is financially stable and ready to invest in future growth.
• Consistent Gross Margins: At 82.85%, Dynavax demonstrates strong efficiency in managing costs.

Negatives (-):

• Sales Decline: Sales are down 27.79% year over year, suggesting challenges in scaling current revenue streams.
• Limited Insider Ownership: Insiders own just 0.42% of the company, potentially indicating less alignment with shareholders.
• Short Interest: A short float of 13.67% reflects market skepticism about its near-term growth.

Bottom Line:

Dynavax is a balanced play for investors seeking exposure to the biotech sector. Its strong institutional support, improving earnings, and promising vaccine pipeline make it attractive, while its declining sales and high short interest remind us of the risks.

If you’re intrigued by DVAX, you’ll want to see the rest of the list.

There are three more stocks with just as much, if not more, potential waiting exclusively for Marathon Money members. Ready to take that step?

Thank you to everyone who has purchased a membership and supported us along the way. Your belief in what we do keeps Marathon Money growing, and we deeply appreciate you being part of this journey.

For those who enjoy this information and want to know when we’re entering these trades or investments, along with our price targets, please leave a comment below or email us. If there’s enough interest, I’ll host an exclusive webinar for members to share even more insights and strategies.

Merry Christmas, Happy Holidays, and Happy New Year! See you in 2025—let’s make some money!